Spironolactone Shows No Outcome Benefit in HFpEF Post-MI, suggests study
A large multicenter retrospective cohort study has found that spironolactone use was not associated with improved clinical outcomes in patients with heart failure with preserved ejection fraction (HFpEF) following acute myocardial infarction.
Heart failure with preserved ejection fraction (HFpEF) following acute myocardial infarction is common, yet evidence-based pharmacotherapy remains limited. This study aims to evaluate the efficacy of spironolactone among patients with HFpEF following acute myocardial infarction.
They conducted a multicenter retrospective cohort study using data from 82 hospitals across China between January 2010 and March 2024. Patients were stratified into spironolactone users versus non-users. Propensity score matching (PSM) was performed to balance baseline covariates. The primary endpoint was a composite of 1-year heart failure rehospitalization or cardiac death. Time-to-event outcomes were analyzed using Kaplan–Meier curves with log-rank tests. Cox proportional hazards models with cluster-robust variance estimation were used to estimate hazard ratios (HRs). Restricted mean survival time (RMST) analysis was applied to assess survival differences when the proportional hazards assumption was violated. Prespecified subgroup analyses were conducted by age (<65 vs. ≥65 years), sex, hypertension, and diabetes mellitus.
Among 4,507 eligible patients, 1,171 matched pairs were included after PSM. Kaplan–Meier analysis showed no significant difference between groups (log-rank P = 0.26). Cox regression yielded an HR of 1.18 (95% CI: 0.89–1.58; P = 0.25). RMST analysis revealed a non-significant difference of −0.6 days (P = 0.845). All secondary endpoints and subgroup analyses were consistent with the null findings for the primary endpoint.
In this large multicenter retrospective cohort study, spironolactone use was not associated with improved clinical outcomes in patients with HFpEF following acute myocardial infarction.
Reference:
Keywords:
Spironolactone, Shows, No, Outcome, Benefit, HFpEF Post-MI, suggests, study, The American Journal of Medicine, Spironolactone, Heart failure with preserved ejection fraction, Acute myocardial infarction, Pharmacotherapy
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.